One of the many concerns about President Obama’s health care legislation is that it will encourage—if not eventually require—the government to approve the cheapest rather than the best ...

Full publication of results from the head-to-head study of Avastin (bevacizumab) and Lucentis (ranibizumab) in "wet" age-related macular degeneration (AMD) confirmed information previously leaked ...

While Avastin is designed to treat cancer, not blindness, many doctors say it works just as well as Lucentis — with significant potential cost savings to patients, insurers, and the government.

The valuation of Genentech shares is "less attractive," said SG Cowen, as blockbuster cancer drug Avastin could limit the potential of the biotech firm's promising blindness treatment, Lucentis.

Inhibitors of vascular endothelial growth factor — bevacizumab (Avastin) and ranibizumab (Lucentis) — are used to treat patients with neovascular age-related macular degeneration. Bevacizumab ...

Avastin and Lucentis: two drugs with roughly the same molecular structure, both manufactured by the same drugmaker. One is approved to treat cancer, the other wet age-related macular degeneration.

The Lucentis/Avastin story is going to get more complicated as the year goes on. Next month the results of a head-to-head study of the two drugs (one far less costly than the other) in cases of ...

If raising the reimbursement rate triggered a mere 8% of Lucentis scripts to switch to Avastin, "you'd be budget-neutral," Dr. Hutton said. "A lesson from this study for US policy makers is that ...

A new study, led by Dr. Daniel Martin, an ophthalmologist at the Cleveland Clinic’s Cole Eye Institute, has found that the cancer drug Avastin delivers the same benefits of the drug Lucentis ...

The Lucentis-versus-Avastin debate just got a bit more complicated. Regeneron Pharmaceuticals ($REGN) won FDA approval for its macular degeneration drug Eylea ...

In other Avastin news, the big trial pitting the cancer drug against Genentech sister med Lucentis is now underway. Sponsored by the National Institutes of Health, the independent trial is ...

It concludes that the company's two drugs, Avastin and Lucentis, are equally effective at treating the leading cause of blindness in people over age 65, but that Roche has manipulated their supply ...